Yener, Ali ÜmitÖzkan, Muhammed Turgut AlperÇiçek, Mustafa CüneytTemIz, Ahmet2025-01-272025-01-2720141307-1173https://hdl.handle.net/20.500.12428/14158Antiplatelet agents are important drugs that are used in the treatment of coronary artery disease (CAD). Antiplatelet therapy especially after an acute coronary syndrome (ACS) is crucial. However, approximately 5% of patients who receive coronary stents are expected to require cardiac or non-cardiac surgery within 1 year after percutaneous coronary intervention (PCI). In this review we discuss the scenarios that can reduce the risk of these patients. It is ideal that non-urgent surgery should be delayed for the time to discontinue antiplatelet therapy confidently. The best approach involves the interdisciplinary teamwork with surgeon, cardiologist, anesthetist and patient which review all the related situations.eninfo:eu-repo/semantics/closedAccessAntiplatelet therapy; Aspirin; Bleeding; Clopidogrel; SurgeryReview Article8146482-s2.0-84893699837N/A